TAVR in Asymptomatic or Minimally Symptomatic Patients: 30-Day Results

Aortic valve replacement (AVR) is recommended for symptomatic aortic stenosis (AS), while close monitoring is the advised strategy for asymptomatic patients, unless they have elevated aortic gradients, reduced ejection fraction, or abnormal stress tests.

TAVI en pacientes asintomáticos o mínimamente sintomáticos: Resultados a 30 días 

However, the optimal timing for AVR remains uncertain, especially in light of recent evidence suggesting that AS patients showing signs of myocardial damage have increased long-term mortality and worse outcomes, even in the absence of symptoms.

In the current era, transcatheter aortic valve replacement (TAVR) procedures offer more favorable risk and recovery profiles compared with conventional surgery. However, a better understanding of this strategy in asymptomatic or minimally symptomatic patients with severe AS is still required.

The aim of this retrospective study was to assess the outcomes in patients with minimal symptoms treated with TAVR due to their severe aortic stenosis.

The primary endpoint (PEP) was defined as a composite of adverse events at 30 days, including death, stroke, major bleeding, stage III acute kidney injury, need for dialysis, and moderate to severe paravalvular leak.

Read also: Treatment and Gender-Based Outcomes for Coronary Bifurcation Stent Placement: Report from the e-ULTIMASTER Registry.

Among 231,285 patients with AS treated with TAVR, 20% had minimal symptoms. The average age was 80 years, and 47.5% of subjects were women. The 1-year survival rate was higher in patients with minimal symptoms compared with those with moderate or severe symptoms (hazard ratio [HR] for death: 0.70 [95% confidence interval (CI): 0.66-0.75]).

Furthermore, patients with minimal symptoms experienced a 2.7-point improvement (95% CI: 2.6-2.9) in the quality of life questionnaire at 30 days and a 3.8-point improvement (95% CI: 3.6-4.0) at one year, in contrast to increases of 32.2 points (95% CI: 32.0-32.3) at 30 days and 34.9 points (95% CI: 34.7-35.0) at one year in more symptomatic patients. Patients with minimal symptoms were more likely to be alive at one year (odds ratio [OR]: 1.19 [95% CI: 1.16-1.23]).

Conclusion

In summary, this study demonstrated that patients with minimal symptoms due to aortic stenosis experienced fewer complications after the procedure and better outcomes at one year after TAVR compared with more symptomatic patients. Randomized clinical trials are needed to confirm the safety and efficacy of TAVR in asymptomatic or minimally symptomatic patients with severe aortic stenosis.

Dr. Andrés Rodríguez.
Member of the Editorial Board of SOLACI.org.

Original Title: Outcomes of Transcatheter Aortic Valve Replacement in Asymptomatic or Minimally Symptomatic Aortic Stenosis.

Reference: Chetan P. Huded, MD, MSC et al J Am Coll Cardiol Intv 202.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Prospective Analysis of the Feasibility of the PASCAL System for Transcatheter Mitral Repair: OneForAll Registry

Courtesy of Dr. Juan Manuel Pérez. Mitral transcatheter edge-to-edge repair (M-TEER) is an effective option for patients with severe mitral regurgitation who are at high...

Left Bundle Branch Block after TAVR: What Is Its Impact?

Courtesy of Dr. Juan Manuel Pérez. Left bundle branch block (LBBB) is a common complication following transcatheter aortic valve replacement (TAVR), which can be either...

Multicenter Experience with 3D Intracardiac Echocardiography for Guiding Interventional Cardiac Procedures

Courtesy of Dr. Juan Manuel Pérez. Imaging techniques play a fundamental role in interventional cardiac procedures. Intracardiac echocardiography (ICE) appears as an alternative to transesophageal...

Pathology of Self-Expanding Transcatheter Aortic Bioprostheses and Hypoattenuated Leaflet Thickening

Courtesy of Dr. Juan Manuel Pérez. Despite the available long term followup data on of transcatheter aortic valve replacement (TAVR), bioprosthesis durability continues under debate....

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...